Tumor flare reaction with brentuximab-vedotin in mycosis fungoides

JAAD Case Reports 2026 Open access

Read full text
Authors: Rishabh Lohray, Seda Pürnak, Samruddhi Arkatkar, Madeleine Duvic, Victor Prieto, Carlos Torres-Cabala, Auris Huen
DOI: 10.1016/j.jdcr.2026.01.051
Cited by: 1
References: 3

Abstract

Brentuximab vedotin (BV) is an anti-CD30 antibody conjugated to the microtubule assembly inhibitor monomethyl auristatin E. It is Food & Drug Administration-approved for the treatment of CD30+ mycosis fungoides (MF) with one of the highest overall response rates (65%), especially in treating tumors and nodal disease. While peripheral neuropathy is the most frequently reported adverse effect, tumor flare reaction (TFR) has rarely been documented. This case report presents a patient with TFR with the intent of educating providers on this phenomenon and preventing unnecessary therapy cessation.

Fields of Study & Subjects

Cutaneous lymphoproliferative disorders research Infectious Diseases and Mycology Autoimmune Bullous Skin Diseases

Publication details

Journal / source
JAAD Case Reports
Publisher
Elsevier BV
Volume
70
Pages
39–41
Publication date
6 February 2026
Language
EN